Biotech Stocks Growth Stocks Healthcare Stocks Life Sciences Mid Cap Stocks Small Caps Stocks

ASX Biotech Investing In 2026: Investors Are More Aware Of The Hard Lessons, But Have Forgotten The Hidden Rewards Of It

ASX Biotech Investing has always been the market’s most difficult arena. Yes tech and resources are risky spaces too, but at least a gold explorer can gain just off the…

ByNick Sundich

16

Mar 2026

Biotech Stocks Healthcare Stocks Life Sciences

Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!

There are plenty of ASX Biotech Targets that major pharmaceutical companies wanting to minimise the impact of the Patent Cliff could look at. For those who don't know what the patent…

ByNick Sundich

04

Feb 2026

Healthcare Stocks

Neuren (ASX:NEU) Crashes 10% on EU Setback: Is This a Buying Opportunity?

Neuren Pharmaceuticals: Is the 10% drop a buy signal? Neuren Pharmaceuticals (ASX: NEU) dropped nearly 10% on Tuesday, falling to A$14.63 from a previous close of A$16.25. The sell-off came…

ByUjjwal Maheshwari

15

Jan 2026

Biotech Stocks

Neuren Pharmaceuticals (ASX:NEU) Surges 6% on US$700m DAYBUE Target: Time to Buy?

DAYBUE royalties could climb fast if US targets land Neuren Pharmaceuticals (ASX: NEU) jumped 6% on Wednesday after its US partner, Acadia Pharmaceuticals, shared big news at the J.P. Morgan…

ByUjjwal Maheshwari

16

Dec 2025

Healthcare Stocks

Neuren Pharmaceuticals (ASX:NEU) Gets FDA Approval- Is It a Buy?

Neuren Pharmaceuticals (ASX: NEU) rose 2.5% yesterday after the US FDA approved DAYBUE STIX, a new powder formulation of its Rett syndrome treatment. The stock has surged 47% over the…

ByUjjwal Maheshwari

21

Oct 2025

Healthcare Stocks

There’s a US$180bn Biotech Patent Cliff coming! Here’s why it could spell doom for large caps, but a generational opportunity for small caps

There's a Biotech Patent Cliff coming over the next decade! Investors aren't giving this much attention, but we think they should because it could cause substantial upheaval in the biotech…

ByNick Sundich

18

Aug 2025

Healthcare Stocks International Stocks

ASX Health Care Stocks Under Trump: Who’ll Win and Who’ll Lose?

What does the next few years hold for ASX Health Care Stocks Under Trump? There's no doubt that the health care sector is bearing a greater brunt than any other…

ByNick Sundich

15

Apr 2025

Healthcare Stocks

Neuren Pharmaceuticals (ASX:NEU): Another exciting chapter is yet to come with NNZ-2591

Neuren Pharmaceuticals (ASX:NEU) is an ASX biotech company that has had a stellar past few years, but it is now facing the question: 'Where to now?' Companies with just one…

ByNick Sundich

01

Oct 2024

Blue Chip Stocks Consumer Dividend Stocks Education Energy Stocks ETF Financials General Healthcare Stocks Index Funds Industrials Large Caps Life Sciences Market news Mid Cap Stocks Mining Stocks Penny Stocks Safe Stocks Small Caps Stocks Tech Stocks Technology Telecommunications Stocks

Want to participate in the ASX Schools Sharemarket Game? Here are Some Top Strategies for Success!

The ASX Schools Sharemarket Game is on again! And it is a great way for school students to be introduced to the strategic functioning of the share markets. But just…

ByUjjwal Maheshwari

09

Oct 2023

Healthcare Stocks

FDA approval: Here’s how ASX biotechs and medtechs obtain it

Last week one of our favourite companies Cyclopharm (ASX:CYC) obtained FDA approval, a goal it had been striving for years to obtain and one that wasn't reached without setbacks along…

ByNick Sundich

ASX Biotech Investing In 2026: Investors Are More Aware Of The Hard Lessons, But Have Forgotten The Hidden Rewards Of It

Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!

Neuren (ASX:NEU) Crashes 10% on EU Setback: Is This a Buying Opportunity?

Neuren Pharmaceuticals (ASX:NEU) Surges 6% on US$700m DAYBUE Target: Time to Buy?

Neuren Pharmaceuticals (ASX:NEU) Gets FDA Approval- Is It a Buy?

There’s a US$180bn Biotech Patent Cliff coming! Here’s why it could spell doom for large caps, but a generational opportunity for small caps

ASX Health Care Stocks Under Trump: Who’ll Win and Who’ll Lose?

Neuren Pharmaceuticals (ASX:NEU): Another exciting chapter is yet to come with NNZ-2591

FDA approval: Here’s how ASX biotechs and medtechs obtain it

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here